Repligen
RGEN
#2055
Rank
$9.51 B
Marketcap
$169.05
Share price
-1.86%
Change (1 day)
10.13%
Change (1 year)
Categories

P/S ratio for Repligen (RGEN)

P/S ratio as of January 2026 (TTM): 13.4

According to Repligen 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.57. At the end of 2025 the company had a P/S ratio of 9.98.

P/S ratio history for Repligen from 2001 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20259.98-22.33%
202412.9-20.43%
202316.237.72%
202211.7-46.29%
202121.8-23.72%
202028.660.6%
201917.849.33%
201811.96.67%
201711.212.2%
20169.97-10.61%
201511.29.27%
201410.259.86%
20136.39103.04%
20123.15-8.06%
20113.42-37.77%
20105.50-10%
20096.1145.49%
20084.20-59.34%
200710.360.41%
20066.44-30.4%
20059.25-9.44%
200410.2-46.53%
200319.166.56%
200211.5-35.84%
200117.9

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Novavax
NVAX
1.21-91.01%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
3.81-71.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
5.23-61.12%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
7.81-41.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
5.30-60.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2.40-82.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
2.29-82.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
8.33-38.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
4.71-64.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
2.65-80.28%๐Ÿ‡บ๐Ÿ‡ธ USA